Last reviewed · How we verify
Albugon (ALBIGLUTIDE)
Albugon (Albiglutide) is a GLP-1 Receptor Agonist, a small molecule developed by GlaxoSmithKline LLC, targeting the glucagon-like peptide 1 receptor. It was FDA-approved in 2014 for the treatment of diabetes mellitus type 2. Albugon works by mimicking the action of the natural hormone GLP-1, which helps regulate blood sugar levels. As a patented medication, its commercial status is subject to ongoing patent protection. Key safety considerations include potential gastrointestinal side effects and increased risk of pancreatitis.
At a glance
| Generic name | ALBIGLUTIDE |
|---|---|
| Sponsor | GSK |
| Drug class | GLP-1 Receptor Agonist |
| Target | Glucagon-like peptide 1 receptor |
| Modality | Recombinant protein |
| Therapeutic area | Metabolic |
| Phase | FDA-approved |
| First approval | 2014 |
Approved indications
- Diabetes mellitus type 2
Common side effects
Key clinical trials
- Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study
- Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
- A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
- Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh (PHASE4)
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period (PHASE3)
- Safety and Efficacy of Albiglutide + Insulin Glargine Versus Insulin Lispro + Insulin Glargine Subjects With Type 2 Diabetes Mellitus (PHASE3)
- Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy? (NA)
- A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Albugon CI brief — competitive landscape report
- Albugon updates RSS · CI watch RSS
- GSK portfolio CI